Effect of yohimbine and its diastereoisomers on clonidine-induced depression of exploration in the rat

Dopamine receptors: molecular biology, biochemistry and behavioural aspects

The description of new dopamine (DA) receptor subtypes, D1-(D1 and D5) and D2-like (D2A, D2B, D3, D4), has given an impetus to DA research. While selective agonists and antagonists are not generally available yet, the receptor distribution in the brain suggests that they could be new targets for drug development. Binding characteristics and second messenger coupling has been explored in cell lines expressing the new cloned receptors. The absence of selective ligands has meant that in vivo studies have lagged behind. However, progress has been made in understanding the function of DA-containing discrete brain nuclei and the functional consequence of the DA's interaction with other neurotransmitters. This review explores some of the latest advances in these various areas.

Alpha 1 (but not alpha 2)-adrenoceptor agonists in combination with the dopamine D2 agonist quinpirole produce locomotor stimulation in dopamine-depleted mice

Mice were premedicated with reserpine and alpha-methyl-p-tyrosine to deplete stores of dopamine (DA) (and other neurotransmitters) and to stop DA (and noradrenaline (NA] synthesis. In DA-depleted mice, the mixed alpha 1/alpha 2 agonist clonidine potentiated locomotor stimulation induced by a low dose of apomorphine as measured in automated activity cages. Clonidine and the slightly alpha 1-selective agonist ST587, but not ST91, an alpha-agonist which does not readily cross the blood brain barrier, produced marked stimulation when combined with the selective D2 agonist quinpirole. The D1 -selective agonist SKF38393 also produced marked excitation when combined with quinpirole. All the selective agonists, bar quinpirole which in some cases produced a significant locomotor stimulation, were relatively inactive when given alone. A "blind" observational analysis of the animals challenged with clonidine plus quinpirole indicated an increase in sniffing, rearing and shaking behaviour. In contrast, observation of the animals challenged with SKF38393 plus quinpirole indicated increased sniffing, rearing and biting and, in one case, increased grooming behaviour. Clonidine did not produce excitation (in automated cages) when combined with the selective D1 agonist SKF38393. The excitation produced by clonidine plus quinpirole was blocked by the selective D2 antagonist raclopride but not by the selective D1 antagonist SCH23390. The stimulation was also blocked by the alpha 1 antagonist prazosin but not by the alpha 2 antagonists idazoxan or yohimbine. Biochemical analysis in the striata of mice challenged with clonidine plus quinpirole did not provide any obvious biochemical basis for the behavioural interaction. It is concluded that alpha 1 receptor agonists in combination with D2 DA agonists can produce marked stimulation in DA depleted mice.

Audiogenic stress response: behavioral characteristics and underlying monoamine mechanisms

Behavioral characterization of the audiogenic stress response in rats revealed an intensity related multiphasic pattern including an initial, transient activation followed by prolonged periods of response suppression during the remainder of the noise exposure and excitation after noise offset. These observations emphasize the need to consider the temporal proximity between exposure to a stressor and either behavioral characterization and/or determinations of neurochemical changes relevant to the stress response. In a second series of studies, the effect of the NE alpha 2 agonist clonidine and the NE alpha 2 antagonist yohimbine were evaluated on the different components of the audiogenic stress response. The effects of intracerebroventricular xylamine-induced depletion of NE were also examined. The results seem to indicate that CNS noradrenergic systems may not be specifically implicated in regulating the responsiveness to noise stimulation but instead may subserve a more general role in adjusting baseline levels of motoric output in response to environmental conditions.

Clonidine-induced sedation is not modified by single or combined neurochemical lesions of the locus coeruleus, the median and dorsal raphe nuclei

Single or combined neurochemical lesions of the locus coeruleus, the dorsal and the median raphe nuclei were performed on different groups of rats. Starting 10 days after the lesion, the locomotor activity of all rats was measured for 5 min every day in an open-field. For the first 21 days all lesioned rats, independently of the lesion site, were significantly less active than controls, but from the 11th to the 16th day the locomotor activity of lesioned animals increased progressively and, thus on days 15 and 16, the mean activity of all lesioned groups was not significantly different from that of the controls. From the 17th day onwards the sedative effect of small doses of clonidine (5-100 micrograms/kg) was measured. Neither single nor combined lesions modified the response to clonidine and the linear decrease of activity produced by increasing doses of clonidine was the same in all groups, lesioned or not. Biochemical assays showed a marked loss of corresponding amines as a result of the lesions in cortex, hippocampus and the brainstem. These results suggest that the alpha 2-receptors involved in clonidine-induced sedation are located neither on noradrenergic fibers coming from the locus coeruleus, nor on serotoninergic fibers originating in the median and dorsal raphe nuclei.

Locomotor depression in mice by norcocaine does not involve central alpha 2-adrenergic or presynaptic dopamine receptors

The inhibition of spontaneous locomotor behavior of mice by norcocaine was antagonized neither by the adrenoceptor antagonists yohimbine and phentolamine, nor by the neuroleptics haloperidol and spiperone, at low doses aimed at presynaptic dopamine receptors. In contrast, the antagonists were effective in reducing the hypomotility induced by clonidine and apomorphine, respectively. These results make it unlikely that central alpha 2-adrenergic or presynaptic dopamine receptors are involved in the hypomotive effect of norcocaine.

A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse

51 purported dopamine agonists from the phenylethylamine, tetralin, octahydrobenzo(f)- and (g)quinoline, benzocycloheptene, aporphine and ergoline series were tested in the mouse for ability to cause motor inhibition at low doses and stereotyped responding (motor facilitation) at higher doses. Motor inhibition was characterised either by a freezing akinesia (spiroperidol sensitive) or by sedation (resistant to spiroperidol). Agents potent to induce the freezing response could, if the dose was raised sufficiently (at least 10 fold), cause stereotypy. Within all series tested N-n-propyl substitution generally conferred greatest selectivity of motor inhibitory action. Radioligand binding assays using [3H]ADTN as ligand and rat striatal tissue showed correlations between abilities to associate with the dopamine receptor and to cause motor inhibition or facilitation, but discrepancies were apparent, particularly within the tetralin series. It is concluded that whilst there exists clear potency differences to inhibit locomotor activity and to induce stereotyped behaviour, it is difficult to demonstrate unequivocally an absolute selectivity of dopamine agonist action for the motor inhibitory dopamine system.

Clonidine and yohimbine separate the sedation and the ptosis caused by cholecystokinin octapeptide and ceruletide

The central depressant effects of ceruletide (CER, 0.04 mg/kg s.c.) and cholecystokinin octapeptide (CCK-8, 0.25 mg/kg s.c.) were compared with those of clonidine (0.04 mg/kg s.c.). At doses that were nearly equipotent with respect to motor inhibition (catalepsy, reduction in ambulation and exploratory rearing), only the peptides produced ptosis. Yohimbine (1 mg/kg s.c., 30 min) antagonized the effect of clonidine but not of the peptides. Clonidine (0.07-0.2 mg/kg s.c., 30 min) antagonised the ptotic action of the peptides, and this effect was abolished by yohimbine (0.2-1 mg/kg i.p.) but resistant to haloperidol (0.05 and 0.15 mg/kg i.p.). These results separate the behavioural effects of the peptides from those of clonidine and also the ptotic effect of the peptides from their effect on motor activity. The antiptotic effect of clonidine may originate from activated adrenergic autoreceptors.

Effects of the training dose on generalization of morphine stimulus to clonidine

The relationship between the stimulus properties of morphine and clonidine was tested in rats trained to discriminate morphine sulfate (4, 2 or 1 mg/kg) from saline in a two-lever food-rewarded task. The response trained in the low dose group generalized to low doses of clonidine (0.125 to 0.5 mg/kg) whereas the response trained with the high dose of morphine generalized only to higher doses of clonidine (0.625 to 1.0 mg/kg). Naloxone blocked the generalization in the low dose group but only partially blocked it in the high dose group. Yohimbine blocked the generalization to clonidine in the high morphine dose group and reversed the response rate suppressant effect of clonidine in all groups.

Development of receptors for dopamine and noradrenaline in rat brain

In order to examine the receptor basis for the development of spontaneous locomotion and for the effects of clonidine in the infant rat, we measured the densities of alpha 1-adrenoceptors, alpha 2-adrenoceptors and D2-dopamine receptors in various brain regions of the developing infant Wistar rat. The mesolimbic D2-dopamine receptors paralleled the rise in spontaneous locomotion of the infant rat. No alpha 1-adrenoceptors were detectable at birth in any of the four regions examined (mesolimbic, hippocampus, frontal cortex, and hypothalamus), thus providing no basis for the locomotor-stimulating action of clonidine in the first week of life. Mesolimbic alpha 2-adrenoceptors matured between 21 and 28 days (at which time clonidine yields its usual sedating action).

Neurochemical lesion of the locus coeruleus of the rat does not suppress the sedative effect of clonidine

The locus coeruleus of male rats was destroyed bilaterally by injection of 6-hydroxydopamine. Rats injected with the vehicle and normal rats served as controls. Starting 20 days after the lesion, the locomotor activity of all rats was measured for 5 min every day. For the first 6 days, the lesioned rats were significantly less active than control rats; from the 7th to the 15th day, on the other hand, the locomotor activity of the two groups of rats was the same. From the 16th day onwards, the sedative effect of small doses of clonidine (2.5-100 micrograms/kg) was measured in lesioned and control animals. In spite of an almost total loss of noradrenaline in the cerebral cortex and hippocampus and a 33% loss of noradrenaline in the brain-stem of the lesioned rats, the sedative effect of clonidine was the same as in the control rats. This result suggests that the sedation produced by clonidine is not dependent on presynaptically located alpha 2-adrenoceptors.

Evidence that behavioural and electrocortical sleep induced by guanfacine is due to stimulation of alpha 2-adrenoceptors

The effects of guanfacine and other drugs acting at alpha 1- and alpha 2-adrenoceptors on behaviour, electrocortical activity and ECoG spectrum power were studied in chicks and rats. Guanfacine, given systematically in chicks, produced behavioural and electrocortical slow-wave sleep lasting 100-200 min, depending on the dose; these effects were prevented by yohimbine, a selective antagonist, at alpha 2-adrenoceptors and potentiated by prazosin, a selective antagonist, at alpha 1-adrenoceptors. Similar behavioural and electrocortical effects were obtained after systemic or intraventricular infusion of guanfacine in rats. In addition, a significant increase in total and in lower frequency band (0-4; 4-8 Hz) voltage power was observed. Behavioural and ECoG effects of guanfacine were prevented by phentolamine or yohimbine, whereas prazosin and propranolol were ineffective. Yohimbine itself, given systemically in chicks, produced behavioural stimulation, vocalization, increase in locomotor activity and ECoG desynchronization, with a significant fall in total and 0-3, 3-6, 6-9 and 9-12 Hz voltage power lasting approx. 3 h. Desipramine, an inhibitor of noradrenaline reuptake, produced in chicks behavioural and ECoG arousal, vocalization, pecking, escape responses and aggressive behaviour. In conclusion, the present experiments show that guanfacine sedative effects seem to be mediated predominantly via an activation of presynaptic alpha 2-adrenoceptors and suggest that arousal is due to stimulation of post-synaptic alpha 1-adrenoceptors.